32 
If, however, the RAC abandons review of rDNA research in 
humans, then the FDA should create a new advisory committee whose 
charter is to review INDS in this area. In the final analysis, 
the FDA will have to set the parameters for those investigations 
in which INDs will be required. An advisory committee 
whose sole task is to provide guidance in this area where 
science and social questions intertwine would be most helpful 
and lead to a better result than if the FDA did it 
alone. 
Outside the pharmaceutical industry for which RAC and 
the FDA will set the regulatory guidelines, the major federal 
agency which will he involved in rDNA experiments is the 
Environmental Protection Agency. The EPA should and will set 
the guidelines for the widespread use of rDNA products 
intentionally released into the environment. This important 
role will be aided by the fact that it is a member of the 
Federal Interagency Committee on Recombinant DNA Research. It 
can put that membership to good use by learning from the FDA how 
it has handled questions regarding rDNA experiments. 
Public Discussion and Understanding of the Benefits of rDNA 
Technology 
Member firms of the PMA have invested and will continue 
to invest heavily in products developed through the use of rDNA 
technology. Because of public awareness that the pharmaceutical 
industry is using this new technology, the PMA as 
[ 633 ] 
